ALS Ltd Stock
Price
Target price
€10.30
€10.30
-
-
-
-
14.08.25 / Frankfurt
WKN: A1J2YC / Name: ALS / Stock / Professional & Commercial Services / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of ALS Ltd in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
S********** s********
Cons
?
G***** c******* t* c**********
?
B****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of ALS Ltd vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| ALS Ltd | - | 0.980% | 5.102% | 14.444% | 15.084% | 26.380% | 90.741% |
| Seek Ltd | - | 1.460% | 2.963% | 11.200% | 2.206% | -17.262% | 17.797% |
| Downer EDI Ltd | - | -1.064% | -0.535% | 31.915% | 19.231% | -2.618% | 48.800% |
| Insperity Inc. | 4.670% | -2.183% | -10.040% | -45.697% | -38.207% | -60.000% | -24.068% |
News
Clene Posts 70% Revenue Drop in Q2
Clene (NASDAQ:CLNN), a clinical-stage biopharmaceutical company developing treatments for neurodegenerative diseases, released its second-quarter 2025 earnings on August 14, 2025. The most important
Brainstorm Posts 43% EPS Gain in Q2
Brainstorm Cell Therapeutics (OTC:BCLI), a biotechnology developer focused on neurodegenerative diseases, released its second quarter 2025 results on August 14, 2025. The headline news was a GAAP
Athira (ATHA) Q2 Loss Narrows 74%
Athira Pharma (NASDAQ:ATHA), a biopharmaceutical company developing drugs for neurodegenerative diseases, released its second quarter results on August 7, 2025. The update centered on its cost